Geron Corp (GERN) 옵션

May 7th is gerons last chance if it does not gain on earnings it is done

May 7th is gerons last chance if it does not gain on earnings it is done

LC2020 _ This was just posted for you incase you missed it...

The Law of Resonance!!!

wonderknow

Re: learningcurve2020 post# 763269

Wednesday, April 23, 2025 9:26:54 AM

Post#
763285
of 763287
You are about to be sued for slander for my friend.

LOLC2Lol@

GERN, under $2

See what i mean this will never see 2 again let alone 6 . Effing crazy

Geron Price Target Maintained With a $5.00/Share by Needham
March 12, 2025
07:34 AM ET

Anyone saying anything good about this company is crazy

Because "Whole", has become a Definer/Reminder of you......

You go... the flag barer of the "Whole" Team...

The Law of Resonance:::::

The second somebody talks about wholes you always seem to pop up?

LOLC2020 ,,
Your statement below truly defines you - Thanks for the clarification...
>>> which is a massive difference if you’re ever trying to get whole again>>>>

Q - Have you past the Point of no return???

Great time to seek "Defensive Stocks" due to economic headwinds caused by tariffs.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176042856

ELTP, an otc gem on the verge of M&A...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175821245

I do. But in this case we have a company with solid institutional holdings and all top management slowly accumulating options through a plan. It doesn’t seem like a candidate for self sabotage. But I do call them “Grrrrron” for a reason. Lots of suffering with this one over all the years.

I hear what you are saying but i think that you also understand what i am saying ?!

Biotech sector is in a slump for the moment so... @7 multiple X 2024 revs ($75M but for only 1/2 year in U.S. only) so about a $1billion market cap current. So maybe $500M in global revs for 2025 / 26 or $3.5B market cap ($5 share price). 🙏. We need word of treating another indication then it’s off to the races! Any buyout would add a few years rev outlook, of course. I have to believe Rytelo is a prime candidate given its unique MOA and manageable side effects? I hope we hear soon on a new CEO unless Interim CEO Bir hits the ground running.

Well it is very clear to me that the people running this company have zero concern for shareholders. This stock has crumbled 75 % since FDA approval. That just cannot happen. It seems to me like they are trying to ruin this company. Im not saying this stock should be up to a 100 but it should be at least 10 . Its unexceptable that it will most likely under 1 dollar soon .

Why rs with only 640M shares outstanding and with 80% institutional holdings? They’ve already said they’re not going to raise cash. It took a while but they’re now FDA approved and generating revenue. With the recent sp hit it seems like a good bet. Just can’t have f ups at bedside.

This will do a reverse split by year end and then file for bankruptcy next year or completely go under . Great company 30 years to get a drug approved and this is what they do to long investors.

LOLC2020 - Your Reward For Your Activities for over 10 years will catch up to you....
What would you call yourself then...? KARMA
___________________
learningcurve2020

Re: Investor082 post# 759936

Wednesday, April 09, 2025 11:52:33 AM

Post#
759938
of 759938
You’ll notice all the pro pumpers have gradually disappeared

Wow!! Its been a long while since i looked at this . Where is that dumbass loudmouth stumblebum?

picked up another 1400@1.29

GERN, new 52 week low

Added 5000 for a flip

LOLC-2020... GERN? Really??? Na.. DUDE......

Let your boss, it is AF (the GERN flipflopper) to know....game over!!

Grrrron. But I’m hanging in there with them. Seems like a prime candidate now for a takeover. Now we see why they dropped the price. Terrible considering the analyst calls.

>> (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

150,000 shares in stock options with an exercise price of $1.74 per share
75,000 shares in restricted stock units (RSUs)
The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Lawsuit:
>>According to the complaint, during the class period, defendants failed to disclose to investors that
Geron’s optimistic reports of Rytelo’s launch success and potential growth fell short of reality; the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied. Moreover, Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting.

The complaint alleges that on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the price of Geron’s common stock declined from a closing price of $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.

Nice another law suit. I received a check for $7,023.42 on the first law suit, lol. maybe I'll pick up another check 😀

LOLC2020 - Karmic Karma!!

Get back in your box, Gimp.

LOLC2020? Marketer for global sales??
Put an add on X.. LOL. LOLC

Possible. But Scarlett was always better at drug development. Plus he’s getting up there. What Geron needs now is a great marketer for global sales.

Perhaps CEO needs to get out of the way for a BO to happen.

And European approval just was announced also

CEO stepping down...

Good news????

LOLC-2020...

SMH

Oh wow, nice! I hadn’t noticed. Always encouraging. Hopefully more to come.

The insiders were bullish buying shares on the open market last Thursday.

Its the "Too Little Tooo Late" story for GERN..
LOLC??? SMH
KARMA

Shouldn’t be down here but it is. Analyst are all over the place. Institutional holdings look good so far unless they’re dumping. We need a more dynamic management, IMO.

“B. Riley downgrades to Neutral from Buy, Cuts target to $2 from $3.50”

looking for 2.25 by next week

Sold the15K at 1.75

That’s all I need too. You know their governance over on the other board is atrocious, right? Rarely leads to anything good. At least Geron’s management bench runs deep. I wish they’d be more active with open market purchases but if the company is really in takeover mode that wouldn’t be possible, of course. Three presentations coming in the next weeks. We’ll see.

Here we agree. On the other board not so much.

By the way, I only have one account on ihub.

It would be one explanation for the action today and faux stock downgrades.

“Wedbush Lowers Geron’s Price Target to $7 from $8, Outperform Raiting Maintained”

The takedown before the buyout!!

The same happen with HGSI

LOLC2020 - You pumped it, Its failing & you now saying "THE COMPANY IS SOLID", BUT the "ANALYSTS SEEM INTENT ON SETTING THE STOCK FOR FAILURE??

Who pays you for such misjudged PUMP Efforts here & FUD Efforts there???

This would be a very good time for some open market purchases by management.

The company seems solid but the analyst seem intent on setting up the stock for failure.

And you think someone would believe that why?

Great purchase. picked up another 5k @ 1.92

All seems good but the stock is always a death trap.

>>Selling, general and administrative expenses for the three and twelve months ended December 31, 2024, were $43.4 million, and $145.7 million, respectively, and $21.4 million and $69.1 million for the same periods in 2023. The increase in general and administrative expenses in 2024 as compared to 2023 primarily reflects higher personnel-related expenses related to increased headcount to support commercial launch of RYTELO in the U.S. and stock-based compensation expense recognized upon FDA approval of RYTELO due to the vesting of performance-based stock options.